A novel cardiac inotropic mechanism that provides functional benefit

一种提供功能益处的新型强心力机制

• 批准号: nhmrc : 526622
• 负责人: A/Pr Elizabeth Woodcock
• 金额: $ 27.6万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-cardiac-inotropic-functional-benefit/97348
• 关键词: novel; cardiac; inotropic; mechanism; provides

Patients with heart failure are often treated with an inotropic agent to increase the force of the heart's contraction and thus improve quality of life for these patients. Most inotropic agents have deleterious effects that limit their usefullness. Mice that have increased alpha1-A receptor expression in their hearts have heightened contactility that is not associated with hypertrophy or arrhythmias. We will use microarray, and si-RNA delivery and signalling studies to identify the mechanism.

患有心力衰竭的患者通常用正性肌力药物治疗以增加心脏收缩的力量，从而改善这些患者的生活质量。大多数正性肌力药具有限制其使用的有害作用。心脏中α 1-A受体表达增加的小鼠具有与肥大或心律失常无关的高接触性。我们将使用微阵列和si-RNA传递和信号研究来确定机制。